Immunome leaps on news of Phase III asset buy

7 February 2024
immunome-large

US clinical-stage biotech Immunome (Nasdaq: IMNM) saw its shares close up 37% at $23.11, after it announced a deal to acquire rights to an investigational Phase III drug for desmoid tumors.

Immunome yesterday disclosed it has entered into a definitive asset purchase agreement with Ayala Pharmaceuticals (OTCQX: ADXS) to acquire the latter’s AL102 and related drug candidate AL101. Ayala’s shares leapt 40% to $1.31yesterday, but were down more than 15% at $1.12 pre-market today.

Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial milestone payments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology